Treatment of unresectable squamous cell carcinoma of the skin with epidermal growth factor receptor antibodies - A case series

European Journal of Dermatology

Volumn 23, Issue 5, 2013, Pages 658-662

  Eder, Johanna ^a,b   Simonitsch Klupp, Ingrid ^c   Trautinger, Franz ^a,b  

^a Karl Landsteiner Institute of Dermatological Research   (Austria)

^b Department of Dermatology and Venereology ^*  (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

EGF receptor antibodies; Palliative treatment; Squamous cell carcinoma of the skin

Indexed keywords

CETUXIMAB; DOXYCYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERYTHROMYCIN; FLUORODEOXYGLUCOSE F 18; IMIQUIMOD; MINOCYCLINE; PANITUMUMAB;

ADVANCED CANCER; AGED; ARTICLE; BONE METASTASIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CANCER SURGERY; CASE REPORT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MALE; PHOTODYNAMIC THERAPY; RADIATION DOSE; RASH; RETROSPECTIVE STUDY; SKIN CARCINOMA; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR VOLUME; VERY ELDERLY; XEROSIS;

EGF-RECEPTOR ANTIBODIES; PALLIATIVE TREATMENT; SQUAMOUS CELL CARCINOMA OF THE SKIN;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MOLECULAR TARGETED THERAPY; NEOPLASM RECURRENCE, LOCAL; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SCALP; SKIN NEOPLASMS;

EID: 84889034505     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2013.2153     Document Type: Article

References (18)

1. Trakatelli M, Ulrich C, del Marmol V, Euvrard S, Stockfleth E, Abeni D. Epidemiology of nonmelanoma skin cancer (NMSC) in Europe: accurate and comparable data are needed for effective public health monitoring and interventions. Br J Dermatol 2007; 156(Suppl 3): 1-7.
2. Diepgen TL, Mahler V. The epidemiology of skin cancer. Br J Dermatol 2002; 146(Suppl 61): 1-6.
3. Alam M, Ratner D. Cutaneous squamous-cell carcinoma. N Engl J Med 2001; 344: 975-83.
4. Schmitt J, Seidler A, Diepgen TL, Bauer A. Occupational ultraviolet light exposure increases the risk for the development of cutaneous squamous cell carcinoma: a systematic review and meta-analysis. Br J Dermatol 2011; 164: 291-307.
5. Weinstock MA. Public health messages regarding skin cancer. J Invest Dermatol 2004; 123: xvii-ix.
6. Belkin D, Carucci JA. Mohs surgery for squamous cell carcinoma. Dermatol Clin 2011; 29: 161-74, vii.
7. Cranmer LD, Engelhardt C, Morgan SS. Treatment of unresectable and metastatic cutaneous squamous cell carcinoma. Oncologist 2010; 15: 1320-8.
8. Kalapurakal SJ, Malone J, Robbins KT, Buescher L, Godwin J, Rao K. Cetuximab in refractory skin cancer treatment. J Cancer 2012; 3: 257-61.
9. Jambusaria-Pahlajani A, Miller CJ, Quon H, Smith N, Klein RQ, Schmults CD. Surgical monotherapy versus surgery plus adjuvant radiotherapy in high-risk cutaneous squamous cell carcinoma: a systematic review of outcomes. Dermatol Surg 2009; 35: 574-85.
10. Maubec E, Petrow P, Scheer-Senyarich I, et al. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol 2011; 29: 3419-26.
11. Khan MH, Alam M, Yoo S. Epidermal Growth Factor Receptor Inhibitors in the Treatment of Nonmelanoma Skin Cancers. Dermatol Surg 2011; 37: 1199-209.
12. Wollina U. Cetuximab in non-melanoma skin cancer. Expert Opin Biol Ther 2012; 12: 949-56.
13. Fogarty GB, Conus NM, Chu J, McArthur G. Characterization of the expression and activation of the epidermal growth factor receptor in squamous cell carcinoma of the skin. Br J Dermatol 2007; 156: 92-8.
14. Kimura H, Sakai K, Arao T, Shimoyama T, Tamura T, Nishio K. Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor. Cancer Sci 2007; 98: 1275-80.
15. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-45.
16. Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005; 16: 1425-33.
17. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008; 358: 1160-74.
18. Maubec E, Duvillard P, Velasco V, Crickx B, Avril MF. Immunohistochemical analysis of EGFR and HER-2 in patients with metastatic squamous cell carcinoma of the skin. Anticancer Res 2005; 25: 1205-10.